Corcept Therapeutics Incorporated CORT shares surged Thursday following a second-quarter earnings beat.
What To Know: Corcept reported quarterly earnings of 25 cents per share which beat the analyst consensus estimate of 15 cents. The company also reported quarterly sales of $117.72 million which beat the analyst consensus estimate of $109.71 million, a 13.86% increase over sales of $103.39 million the same period last year.
On Thursday, the company had its price target raised by three analysts.
- HC Wainwright & Co. analyst Swayampakula Ramakanth maintained Corcept Therapeutics with a Buy and raised the price target from $30 to $32.
- Truist Securities analyst Gregory Fraser maintained Corcept Therapeutics with a Hold and raised the price target from $26 to $29.
- Piper Sandler analyst David Amsellem maintained Corcept Therapeutics with a Overweight and raised the price target from $27 to $31.
Related Link: Why Is Schrödinger Stock Tumbling Today?
CORT Price Action: Shares of CORT were up 25.5% at $31.38 at the time of publication, according to Benzinga Pro.
Image by Steve Buissinne from Pixabay
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.